2024年10月，苏州晶云药物科技股份有限公司（以下简称“晶云药物”）即将参与一系列重要的线下行业活动，我们诚挚地邀请您与我们一同相聚苏州、San Francisco、San Diego以及Salt Lake City，共同探讨行业前沿，分享创新技术。
行业会议
01
SAPA-China 2024
医药产业大会
10/18-19 | 苏州
请点击查阅详情 ↑
“SAPA-China 2024医药产业大会-弘扬创新合作，加快产业融合”将于2024年10月18-19日在苏州·狮山国际会议中心举办。届时将有7000余位来自全球顶尖科研机构的学者以及大型跨国制药及生物技术创新企业领军人物等参会,大会围绕大/小分子、细胞基因治疗、AI制药、核酸GLP-1与代谢、临床、核素偶联药物、出海合作、投融资等热点领域主题,举办高层论坛专题论坛、项目对接、融资推介、企业展示等系列活动。
时间：2024年10月18-19日
地点：苏州狮山国际会议中心
展位：A23
海外活动
02
The 16th Drug Discovery Strategic Summit (DDSS) - San Francisco
10/9-10 PDT | San Francisco, CA
Date: October 9-10, 2024
Location: San Francisco Airport Marriott Waterfront
Booth: 3
Attendee: Robert Wenslow, Ph.D. (Speaker) & Ridwan Islam, Ph.D.
Presentation title:
“The Best Use of 10 mg” - Achieve CMC Success through a Unique Optimization of Compound Benchwork and Computational Analysis
Abstract: Small Molecule drug discovery scientists have been trained to believe that they need gram scale quantities of API to determine CMC properties such as solubility, oral absorption, and salt selection to understand the formulation strategy. Crystal Pharmatech will unveil its proven approach to understanding the developmental risks through focused laboratory work and the most advanced computational approaches. You will understand how, with only 10 mg of material, you can move from late lead-op to FIH with a line-of-sight of your compound’s development path and significantly enhance your probability of success in the clinic.
Link: https://ddsswc.agilefalconsg.com/event-guide/
03
Formulation & Delivery US 2024
10/16-17 PDT | San Diego, CA
Date: October 16-17, 2024
Location: DoubleTree by Hilton Hotel San Diego - Mission Valley
Booth: 12
Attendee: Jessica (Xiaoxia) Chen, Ph.D. (Speaker) & Decheng Ma, Ph.D.
Presentation title:
First in Human (FIH) Tablet Development for an Amorphous Unstable Prodrug with Enteric Coating Using an API Sparing Approach
Abstract: This presentation will explore the formulation and development process of First-In-Human (FIH) enteric-coated tablets at three dose strengths for an amorphous prodrug highly susceptible to hydrolysis under both acidic and basic conditions. We will delve into the scientific approaches employed to mitigate degradation pathways, ensure product stability through carefully selected excipients and optimized manufacturing techniques, and how material science-based approaches can lead to successful FIH product development within tight timelines.
Link: https://oxfordglobal.com/discovery-development/events/formulation-delivery-us-2024
04
AAPS 2024 PHarmSCi 360
10/20-23 MDT | Salt Lake City, UT
Meet with industry leadership to discuss:
Developability Assessment
API Form and Solid-State Research
Formulation Development
Clinical and Commercial Manufacturing
Biologics Analytical Services
Date: October 20-23, 2024
Location: Salt Palace Convention Center, Salt Lake City, UT
Attendee: Alex Chen, Ph.D. & Robert Wenslow, Ph.D. & Decheng Ma, Ph.D. & Ridwan Islam, Ph.D.
Booth: 3139
Link: https://www.aaps.org/pharmsci/annual-meeting
关于晶云药物
晶云药物是一家技术驱动的，专注于药物晶型研究、制剂开发和生产以及临床供应的CRO/CDMO，致力于为小分子新药客户提供量身定制的“首次正确”的晶型和制剂，将您处于先导优化或临床前候选阶段的化合物快速推进至临床I期及更远阶段，提升其在同类靶点和疾病领域的竞争力，最大化其商业价值。
晶云药物成立于2010年，在中国苏州、美国新泽西和加拿大多伦多均设有研发和生产中心，拥有一支超过250人的专业团队。凭借创新技术和扎实的科学能力，晶云药物与全球1000多家制药企业展开合作，为2000多个新药化合物提供专业技术方案：
• 在中国排名前20的创新药企业里，有19家选择了晶云药物的服务。
• 在全球排名前10的制药企业里，有8家是晶云药物的客户。
我们期待成为您的合作伙伴，帮助您加速新药研发，让人们早日用上高质量药物。
http://www.crystalpharmatech.com.cn
contact@crystalpharmatech.com
晶云大厦·苏州工业园区江韵路288号
